IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1247-1256

  Di Conza, Giusy ^a,d   Buttarelli, Marianna ^a,b   Monti, Olimpia ^a   Pellegrino, Marsha ^a,c   Mancini, Francesca ^a,c   Pontecorvi, Alfredo ^c   Scotlandi, Katia ^e   Moretti, Fabiola ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b Breast Unit   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MUTANT PROTEIN; NSC 652287; PROTEIN MDM2; PROTEIN P53; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENIC ACTIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FURANS; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, IGF TYPE 1; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84862555878     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0913     Document Type: Article

References (50)

1. Paulussen M, Frohlich B, Jurgens H. Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs 2001;3:899-913. (Pubitemid 34074816)
2. Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 2009;10:126-40.
3. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59:111-37.
4. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 2009;69:7140-50.
5. Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-37. (Pubitemid 26362087)
6. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47. (Pubitemid 27053464)
7. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, et al. EWS fli-1 antisense nanocapsules inhibits Ewing sarcomarelated tumor in mice. Biochem Biophys Res Commun 2000;279:401-6. (Pubitemid 32016729)
8. Erkizan HV, Uversky VN, Toretsky JA. Oncogenic partnerships: EWSFLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res 2010;16:4077-83.
9. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulinlike growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7. (Pubitemid 27527522)
10. Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest 1990;86:1806-14.
11. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4. (Pubitemid 26338048)
12. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene 2010;29:4504-16.
13. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14:6364-70.
14. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011;8:25-37.
15. Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA, et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol 1999;56:478-84. (Pubitemid 29406874)
16. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004;10:1321-8. (Pubitemid 40022713)
17. Espinoza-Fonseca LM. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer. Theor Biol Med Model 2005;2:38.
18. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010;9:1847-55.
19. Girardini JE, Del Sal G. Improving pharmacological rescue of p53 function: RITA targets mutant p53. Cell Cycle 2010;9:1847-55.
20. Van Valen F. Ewing's sarcoma family of tumors. In:Masters JRW, Palsson B, editors. Human cell culture vol I. The Netherlands: Kluwer Academic Publisher; 1999. p. 55-85.
21. Bagnara GP, Serra M, Giovannini M, Badiali M, Stella M, Montaldi A, et al. Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). Int J Cell Cloning 1990;8:409-24. (Pubitemid 20359751)
22. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010;49:40-51.
23. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene 1992;7:127-33.
24. Liu W, He L, Ramirez J, Ratain MJ. Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. Clin Cancer Res 2009;15:7602-7.
25. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 1999;57:1283-95. (Pubitemid 29185150)
26. Scotlandi K, Benini S, Manara MC, Serra M, Nanni P, Lollini PL, et al. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 2000;18:959-66.
27. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005;92:2097-101. (Pubitemid 40966242)
28. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009;69:6241-8.
29. Spinnler C, Hedstr€om E, Li H, de Lange J, Teunisse AF, Verlaan-de-Vries M, et al. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of Hdmx. Cell Death Differ 2011;18:1736-45.
30. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009;15:441-53.
31. Saha MN, Jiang H, Mukai A, Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther 2010;9:3041-51.
32. Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One 2007;2:e340.
33. Mathur RS, Mathur SP. In vitro downregulation of growth factors by insulin-like growth factor binding protein-3 in cervical cancer. Gynecol Oncol 2003;91:410-5. (Pubitemid 37346337)
34. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004;24:7275-83. (Pubitemid 39014452)
35. Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A 2003;100:8247-52. (Pubitemid 36842530)
36. Sehat B, Andersson S, Girnita L, Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 2008;68:5669-77.
37. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009;15:171-83.
38. Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 1997;17:7306-16. (Pubitemid 27505960)
39. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005;280:19166-76. (Pubitemid 41379623)
40. Higashi Y, Sukhanov S, Parthasarathy S, Delafontaine P. The ubiquitin ligase Nedd4 mediates oxidized low-density lipoprotein-induced downregulation of insulin-like growth factor-1 receptor. Am J Physiol Heart Circ Physiol 2008;295:H1684-9.
41. Beljanski M, Beljanski MS. Three alkaloids as selective destroyers of cancer cells in mice. Synergy with classic anticancer drugs. Oncology 1986;43:198-203. (Pubitemid 16121737)
42. Sasiela CA, Stewart DH, Kitagaki J, Safiran YJ, Yang Y, Weissman AM, et al. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J Biomol Screen 2008;13:229-37. (Pubitemid 351322873)
43. Fang S, Jensen JP,Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000;275:8945-51. (Pubitemid 30180252)
44. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven BA, Box G, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009;29:2243-53.
45. Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008;141:445-53. (Pubitemid 351550548)
46. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, Lefkowitz RJ, et al. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 2005;280:24412-9. (Pubitemid 40934525)
47. Froment P, Dupont J, Christophe-Marine J. Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 2008;7:3098-103.
48. Mackintosh C, Ordóñez JL, García-Domínguez DJ, Sevillano V, Llombart- Bosch A, Szuhai K, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2012;31:1287-98.
49. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003;1:1009-16. (Pubitemid 38044976)
50. Huang H-Y, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or 16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005;23:548-58. (Pubitemid 46224232)